MedTrace Logo

APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE

NCT05110664 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-11-08

No results posted yet for this study

Summary

A double-blind, cross-over, placebo-controlled, proof-of-concept study using oral peptide YY3-36 solution to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity. The aim of this study is to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity.

Conditions

Interventions

DRUG

PYY (3-36) Peptide

oral PYY3-36 solution

DRUG

Placibo

oral placebo solution

Sponsors & Collaborators

  • Gila Therapeutics, Inc.

    collaborator INDUSTRY

  • University College, London

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2022-08-31
Completion
2022-10-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05110664 on ClinicalTrials.gov